Septic Shock
Conditions
Keywords
sepsis, vitamin-c, thiamine, septic shock
Brief summary
Introduction: Septic shock leads to high morbidity and mortality in critically ill patients. Several lower-case scientific studies have supported the synergistic positive effect of vitamin C, thiamine, and hydrocortisone on sepsis-induced organ dysfunction. Aim: Our aim was to investigate the effect of vitamin complex on organ failure, laboratory parameters, respiratory and antibiotic treatment, intensive care time, and mortality in septic shock patients. Material and methods: In our retrospective and prospective analysis, we collected parameters from 43 (23 vitamin-treated, 20 control) septic shock patients. Patients treated with vitamin, they received vitamin C (4x1500 mg), thiamine (2x200 mg) for three days (2). In other respects, and for hydrocortisone (200 mg / 24h), both groups of patients received treatment according to the European Sepsis Recommendation. SPSS (V-21) data were used for data collection, Kolmogorov-Smirnov, Wilcoxon, Mann-Whitney U tests were used for statistical analysis. Ethical license: 7849-PTE 2019.
Interventions
DRUGVitamin C
Patients in the intervention group (G1) (n=23) received the combined vitamin therapy: IV vitamin C (1.5 g every 6 hours administered as an infusion over 30 to 60 minutes and mixed in a 100- mL solution of normal saline), hydrocortisone (100 mg in bolus-100 mg in perfusor up to 60 min (200mg 24h),), and thiamine (200 mg every 12 hours administered as an infusion over 30 to 60 minutes and mixed in a 100-mL solution of normal saline) for 3 days.
Sponsors
University of Pecs
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* septic shock * intensive care unit administration
Exclusion criteria
* under age 18 * above age 80 * moribund patients * pregnant patients * active kidney stone * inability to obtain consent * viral or mixed sepsis * missed dose of vitamin C/ thiamin or hydrocortisone * Physician refused * Vitamin C / Thiamine/ Hydrocortisone for other indications
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| main mortality | intensive care unit discharge (up to 90 days) | all-cause mortality (dead/survived) in the intensive care unit |
| ventilation | intensive care unit discharge (up to 90 days) | duration of mechanical ventilation (days) |
| vasopressors | intensive care unit discharge (up to 90 days) | length of circulatory support (days) |
| Length of stay | intensive care unit discharge (up to 90 days) | length of Intensive care unit staying (days) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| secondary outcomes | up to 5 days after admission to intensive care | development of inflammatory laboratory parameters: \- se-carbamide (mg/dl) |
| antibiotics | intensive care unit discharge (up to 90 days) | the length of antibiotic treatment (days) |
| PiCCO parameters | up to 5 days after admission to intensive care | changes in invasive hemodynamic parameters-PiCCO ®: \- cardiac index (l/min/m2) |
| other mortality's | up to 60 days after admission to intensive care | in-hospital, 30- and 60-day mortality (dead/survived) |
Countries
Hungary
Outcome results
None listed